Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posted in Alzheimer's Disease, Etiology, Innovations in Neurophysiology & Neuropsychology, Pharmacotherapy and Cell Activity | Tagged Alzheimer, Alzheimers Disease, Conditions and Diseases, MRI, Neurological Disorders, PET, TEDMED | 2 Comments

2 Responses

1. on September 30, 2012 at 7:27 PM | Reply larryhbern

   There may be hope on the treatment side. I don’t know how early you can identify it in practice. They can pick it up several years early, but you have to have a CPT code to do the PET scan. So i don’t know how many people would be affected.

   Loading...

   
   
2. on May 6, 2013 at 5:05 AM | Reply Alzheimer’s disease and one-carbon metabolism | Pharmaceutical Intelligence

   I actually consider this amazing blog , “SAME SCIENTIFIC IMPACT: Scientific Publishing –
   Open Journals vs. Subscription-based « Pharmaceutical Intelligence”, very compelling plus the blog post ended up being a good read.
   Many thanks,Annette

   Loading...